This round of financing attracted support

[shapanwwuom]

From several new strategic investors, such as EQT and Alpha JWC Ventures. Among them, EQT Group is a Swedish private equity investment company that manages funds ranked first in Europe and among the top three in the world. The injection of top capital will provide strong capital support for Connosten to expand its European market. Alpha JWC Ventures, a leading venture capital firm in Southeast Asia, will play a key role in helping Connosten further expand into the Southeast Asian market with its deep market insights and rich investment experience.

As an enterprise born in the Guangdong-Hong Kong-Macao Greater Bay Area, the company has also received investment from the Innovation and Technology Venture Capital Fund of the Innovation and chinese student data Technology Commission of the Hong Kong Special Administrative Region Government. The support and participation of high-quality investors is not only a recognition of Connext’s innovation and globalization capabilities, but will also help Connext reach greater heights on its journey toward globalization strategy.

Cornerstone Robotics adheres to the corporate mission of " making surgery safe and broadening life " , insists on independent innovation, and is committed to building a safe and efficient surgical robot platform. After five years of rapid and high-quality development, Connosten has established three R&D centers around the world, fully mastering core technologies such as mechanical architecture, electrical architecture, software architecture, complex algorithms, and visual imaging, and independently building the underlying technical platform for surgical robots.

Has a mass production factory of over 10,000 square meters in the Greater Bay Area, successfully realizing the " independent research and development, independent manufacturing " of surgical robots . 2024 is the first year of commercialization of Connosten. The company's independently developed Sentire® laparoscopic surgical robot was officially approved for marketing by the China National Medical Products Administration (NMPA) on September 29, 2024.